(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.

Title(18)F-FDG PET database of longitudinally confirmed healthy elderly individuals improves detection of mild cognitive impairment and Alzheimer's disease.
Publication TypeJournal Article
Year of Publication2007
AuthorsMosconi L, Tsui WHon, Pupi A, de Santi S, Drzezga A, Minoshima S, de Leon MJ
JournalJ Nucl Med
Volume48
Issue7
Pagination1129-34
Date Published2007 Jul
ISSN0161-5505
KeywordsAged, Aged, 80 and over, Alzheimer Disease, Databases, Factual, Female, Fluorodeoxyglucose F18, Humans, Longitudinal Studies, Male, Middle Aged, Positron-Emission Tomography, Radiopharmaceuticals, Reference Values
Abstract

UNLABELLED: The normative reference sample is crucial for the diagnosis of Alzheimer's disease (AD) with automated (18)F-FDG PET analysis. We tested whether an (18)F-FDG PET database of longitudinally confirmed healthy elderly individuals ("normals," or NLs) would improve diagnosis of AD and mild cognitive impairment (MCI).

METHODS: Two (18)F-FDG PET databases of 55 NLs with 4-y clinical follow-up examinations were created: one of NLs who remained NL, and the other including a fraction of NLs who declined to MCI at follow-up. Each (18)F-FDG PET scan of 19 NLs, 37 MCI patients, and 33 AD patients was z scored using automated voxel-based comparison to both databases and examined for AD-related abnormalities.

RESULTS: Our database of longitudinally confirmed NLs yielded 1.4- to 2-fold higher z scores than did the mixed database in detecting (18)F-FDG PET abnormalities in both the MCI and the AD groups. (18)F-FDG PET diagnosis using the longitudinal NL database identified 100% NLs, 100% MCI patients, and 100% AD patients, which was significantly more accurate for MCI patients than with the mixed database (100% NLs, 68% MCI patients, and 94% AD patients identified).

CONCLUSION: Our longitudinally confirmed NL database constitutes reliable (18)F-FDG PET normative values for MCI and AD.

DOI10.2967/jnumed.107.040675
Alternate JournalJ Nucl Med
PubMed ID17574982
Grant ListAG022374 / AG / NIA NIH HHS / United States
AG08051 / AG / NIA NIH HHS / United States
AG12101 / AG / NIA NIH HHS / United States
AG13616 / AG / NIA NIH HHS / United States
M01RR0096 / RR / NCRR NIH HHS / United States
Related Institute: 
Brain Health Imaging Institute (BHII)

Weill Cornell Medicine
Department of Radiology
525 East 68th Street New York, NY 10065